Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BEWI – Approval and publication of a prospectus supplement

Reference is made to the stock exchange announcement published by BEWI ASA ("BEWI" or the "Company") on 1 October 2021, 15 October 2021, and 1 July 2022 regarding the Company's acquisition of Jackon Holding AS ("Jackon") (the "Jackon Transaction"). Reference is further made to the stock exchange announcement on 21 February 2021 regarding the approval and publication of a prospectus prepared by BEWI for the listing of the consideration shares to be issued in connection with the closing of the Company's acquisition of Jackon (the "Prospectus"). The Financial Supervisory Authority of Norway

Supply agreement signed with Region Östergötland for wound healing products

Region Östergötland has announced that they intend to sign a direct purchase agreement for items within S2Medical AB (publ)’s wound healing portfolio. The region has not yet announced an estimated quantity or duration of the contract. Information regarding quantity and duration may be announced after the agreement is signed by both parties.   S2Medical's wound healing portfolio consists of several different products that facilitate all the phases of wound healing and contribute to a significantly improved quality of life, for the patients and a significantly reduced cost of care.

Publication of Raute Corporation's interim report and invitation to a briefing

RAUTE CORPORATION INVESTOR NEWS 14 OCTOBER 2022PUBLICATION OF RAUTE CORPORATION'S INTERIM REPORT AND INVITATION TO A BRIEFING   Raute Corporation will publish its Interim Report for January 1-September 30, 2022 (9 months) on Friday, October 21, 2022 at about 9 a.m. Finnish time. A briefing for analysts, investors and the media will be organized on the same day October 21, 2022 at 2:00 - 3:00 p.m.   Venue: Scandic Simonkentta Hotel, Simonkatu 9, Helsinki.   Please inform of your participation in the briefing at the latest on Wednesday, October 19, 2022 to Raute

Cantargia reaches recruitment milestone and focuses nadunolimab development on upcoming randomized studies

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced that the clinical trials CAPAFOUR and CESTAFOUR have enrolled enough patients to halt recruitment. Preliminary results show acceptable safety of the chemotherapy combinations with Cantargia’s lead asset, the IL1RAP-binding antibody nadunolimab (CAN04), as well as signs of efficacy in a cohort of non-small cell lung cancer (NSCLC) patients treated with nadunolimab and gemcitabine/cisplatin in CESTAFOUR. Consequently, clinical development of nadunolimab will focus on planned randomized trials in the lead indications. Additionally,

Flowscape receives expansion order with global customer

A large global customer is expanding its installation to meet the hybrid way of working  by expanding Flowscape's solution to additional offices and more users. The order value for the first year is SEK 1,220,000 (111,000 Euro) and thereafter SEK 77,400 (7,002 Euro) annually recurring."We have been working with the customer since 2016 and supporting them in different phases. Before the pandemic, there was a great focus on solutions for efficient room booking , during the pandemic the interest changed

EQT Infrastructure broadens investor base in GlobalConnect

· EQT Infrastructure welcomes Mubadala as an investor in GlobalConnect  · The broadened investor base adds new resources and expertise, supporting GlobalConnect’s long-term ambition to increase societies’ digital connectivityEQT is pleased to announce that the EQT Infrastructure III and IV funds (“EQT Infrastructure”) have signed an agreement to sell a minority stake in GlobalConnect (the “Company”) to Mubadala Investment Company (“Mubadala”). Having been invested in the Company since 2017, EQT Infrastructure will remain as the largest owner following the closing of the transaction.

AegirBio announces first clinical saliva TDM study in US

PRESS RELEASE                      October 14, 2022 AegirBio is pleased to announce the initiation of a clinical study to evaluate saliva based measurements of natalizumab in multiple sclerosis patients. The goal of the study is to confirm that our novel saliva calibration method can be used to accurately measure therapeutic drug levels in saliva as compared to blood. The study is being performed in collaboration with Dr. John Foley at the Rocky Mountain MS Clinic in Salt Lake City.“To our knowledge, this is the first such study of its kind and will hopefully open the door to non-

Members of the Nomination Committee for Episurf Medical’s Annual General Meeting in 2023

In accordance with decision by the Annual General Meeting, Episurf Medical’s Nomination Committee shall consist of four members. The members are selected by the three largest shareholders in the company that wish to participate in the committee. In addition, the Chairman of the Board is to be appointed to the Nomination Committee. In accordance with the above principles, the Nomination Committee consists of the following four members: · Dennis Stripe, Chairman of the Board of Episurf Medical AB · Sebastian Jahreskog · Johan Wadell, representing Andra AP-fonden · Robert

Waystream’s best ever quarter

The third quarter was Waystream's best ever, with revenue growth of 89% and a 236% improvement in operating result compared to 2021. Underpinning this is that we continue to see great demand for our products, from both new and existing customers, while simultaneously increasing the production rate as planned in order to meet the increased demand. We have secured more new customers during the first nine months of the year than in all of 2020 and 2021 combined, while not losing a single customer. It is especially gratifying that at the beginning of September we were able to present a

Enrolment completed and recommended phase II dose reached for OXC-101

Oxcia AB, today announced that it has completed enrollment and evaluation of the last patient in the MASTIFF Phase I clinical trial of OXC-101 in escalating doses for the treatment of patients with advanced solid malignant tumours. The recommended phase II dose has now been determined.  Study results will be reported the coming months.   “Completing enrolment in the MASTIFF study and determining the Phase 2 Recommended Dose are very significant milestone for our company and allows us to finalize planning of our phase II study” said Austin Smith, M.D, Chief Medical Officer, Oxcia. “We

Bonava publish restated comparative numbers due to the divestment of St. Petersburg

Bonava announced on the 7th of October that we have entered into an agreement to divest Bonava’s subsidiaries in Russia. As a result, the St. Petersburg operations will be reported as discontinued operations from the third quarter 2022. Restated comparative numbers have been published on Bonavas website.In the third quarter 2022 the result of the operations in St. Petersburg will be reported as result from discontinued operations. Bonava Group financial data for prior periods have been restated showing group figures without the St. Petersburg operations. Restated comparative numbers have

Dates for SSAB’s financial reports in 2023

Dates for SSAB’s financial reports in 2023 and the AGM. January 27, 2023             Year-end report for 2022April 26, 2023                  Q1 – Interim report for January-March 2023July 21, 2023                   Q2 – Interim report for January-June 2023October 25, 2023             Q3 – Interim report for January-September 2023 Reports are published at 7.30am CET/CEST on the release date unless otherwise announced. The Annual Report for 2022 will be published during week 12. The Annual General Meeting 2023 will be held in Oxelösund on April 18, 2023. For

Merger with wholly owned subsidiary completed

Reference is made to previous announcements regarding the merger between Aker BP ASA ("Aker BP") and its wholly owned Dutch subsidiary ABP Energy Holding B.V ("AEH"). The merger has now been completed. Consequently, Aker BP has assumed all assets, rights and obligations of AEH, and AEH has simultaneously been dissolved. The merger has been executed without merger consideration and Aker BP’s share capital remains the same.

Presentation of 3[rd] quarter 2022 results

Atea ASA will present its 3[rd] quarter 2022 financial results on Thursday, 20 October 2022 at 08:00 CEST. The presentation will be held at Thon Hotel Vika Atrium, Munkedamsveien 45, Oslo, Norway. In addition to presenting the 3[rd] quarter 2022 results, the company will provide an update on the business. The quarterly report, presentation material, and webcast will be available at:https://www.atea.com/investors/financial-reports/ For further information, please contact:Robert Giori, CFO, Atea ASA, mobile (+47) 934 09 188  About AteaAtea is the leading supplier of IT

OrderYOYO raises ARR and EBITDA guidance for 2022

Company Announcement No. 34 -2022 OrderYOYO A/SInside Information   Copenhagen, October 14, 2022 Consolidated 2022 guidance raised As the merger with app smart progress successfully and due to strong performance in Q3 2022 despite difficult market conditions where OrderYOYO has been taking market share in all major markets consolidated guidance is raised again as follows: •          December 2022 annualized ARR guidance is raised from DKK 180-195m to DKK 185-200m •          EBITDA before other external costs full-year 2022 guidance is raised from DKK (10)-0m to DKK (5)

Artificial Solutions: Invitation to presentation of Q3 report 2022

Artificial Solutions® (SSME:ASAI ), the leading specialist in enterprise-strength conversational AI, will release the interim report for the third quarter of 2022 and new financial targets on Monday 17th October at 12:00 pm (CET).The full report and a brief presentation will be available on: www.investors.artificial-solutions.com/financial-reports. Conference Call – details Per Ottosson, CEO and Fredrik Törgren, CFO will present the financial results and new financial targets. The presentation

MapsPeople – Announcement of extraordinary general meeting

MapsPeople A/S | Notice convening extraordinary general meetingCompany Announcement No. 15 - 2022 Aalborg, October 14, 2022  Extraordinary general meeting of MapsPeople The board of directors hereby convenes to an extraordinary general meeting in MapsPeople A/S, to be held on 1 November 2022 at 16:00 CET on Stigsborgvej 60, 9400 Nørresundby  Agenda 1. Election of a new member of the board of directors 2. Any other business Re agenda item 1 The board of directors proposes that Michael Gram, current CEO of MapsPeople, is elected as a new member of the board of

Swiss Real Estate Award - Manufacturer Innovation: GF Piping Systems nominated with the Hycleen Automation System

The company received one of the three nominations for its Hycleen Automation System that makes drinking water systems safer and more energy efficient.The Hycleen Automation System by GF Piping Systems has been nominated for the category “Manufacturer Innovation” by the jury of the Swiss Real Estate Award. The submitted products were evaluated according to their innovation, sustainability, originality, service offers, customer benefits, the plausibility of their marketing and sales strategies, and their user-oriented architecture. GF Piping Systems developed the Hycleen Automation System

BOMAG receives the Empolis Customer Solution Award 2022

Kaiserslautern, Germany, October 14, 2022 – During the "Empolis:Exchange Summit 2022", BOMAG GmbH was awarded the "Empolis Customer Solution Award 2022". The company, headquartered in Boppard, is a leader in compaction technology and a manufacturer of machines for compacting soil, asphalt and waste. With the award, Empolis annually recognizes successful collaboration in the implementation of intelligent, digital service solutions. This year, BOMAG GmbH was honored for its BIP (BOMAG-Information-Plattform) service platform and the associated Field Service App, which provides all service

Patient recruitment completed in landmark Tourette syndrome study

(Stockholm, 14 October 2022.) Asarina Pharma has completed the recruitment of patients to its Phase IIa clinical study in Tourette syndrome with a total of 28 patients enrolled and the last patient randomized on October 14. The dropout rate in the study remains unexpectedly low. Topline results are expected at the end of Q1 2023. The study compound, Sepranolone, is an endogenous neurosteroid, an entirely new treatment modality for Tourette. It has demonstrated a strong safety prolife in multiple previous clinical studies, and reduced tics without inducing any motor side effects in previous

Saab doubles their XMReality Remote Guidance license holding

As communicated back in October 2020 , Saab who serves the global market with services and solutions within military defense and civil security, and XMReality signed a three-year contract. Saab has now ordered additional licenses as their use is increasing. The additional licenses will double the number of licenses that Saab holds.“Saab is a great company with a long history of excelling at their work with regulatory and security

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 210 - 14 OCTOBER 2022 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 158/22. A/S Motortramp participates in NORDEN’s share buy-back program by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in NORDEN.     Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Thomas France, Investor

Invitation to presentation of Bulten’s Q3 report 2022

Bulten’s interim report for the period January – September 2022 will be published on Thursday 27 October at 1:30 p.m. CEST.A live presentation for analysts, media and investors will be held the same day at 3:30 p.m. CEST where President and CEO Anders Nyström and CFO Anna Åkerblad will be commenting the result. The presentation will be held in English and include a Q&A session. Date: Thursday, October 27Time: The report will be published at 1:30 p.m. CEST and the webcasted telephone conference starts at 3:30 p.m. CEST. The report will be available here:https://www.bulten.com/en/IR?

Change in Aiforia Technologies Plc’s Management Team

Aiforia Technologies Plc, Company release, 14 October 2022, 10:30 a.m. EEST. Aiforia Technologies Plc reinforces its Management Team to accelerate the implementation of the company’s growth strategy.Thomas Westerling-Bui has, as of October 14th 2022, been appointed as Chief Commercial Officer of Americas and as a member of the Management Team (previously Vice President of AI Solutions & Strategy). Thomas joined Aiforia in 2018 and has been instrumental in establishing the US subsidiary and strengthening Aiforia’s position in the market. Thomas received his Ph.D. with honors from the

There are no items matching the current filter
There are no more items matching the current filter
Back to top